Cargando…

Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy—preliminary observations from a high‐volume transplant centre

BACKGROUND: Patients with newly diagnosed dilated cardiomyopathy (DCM) and advanced heart failure have a very high morbidity and mortality with an unpredictable clinical course. We investigated the role of cardiovascular magnetic resonance (CMR) imaging using late gadolinium enhancement (LGE) in thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Venero, Jose V., Doyle, Mark, Shah, Moneal, Rathi, Vikas K., Yamrozik, June A., Williams, Ronald B., Vido, Diane A., Rayarao, Geetha, Benza, Raymond, Murali, Srinivas, Glass, Jerry, Olson, Peter, Sokos, George, Biederman, Robert W.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034795/
https://www.ncbi.nlm.nih.gov/pubmed/27708858
http://dx.doi.org/10.1002/ehf2.12041
_version_ 1782455329200537600
author Venero, Jose V.
Doyle, Mark
Shah, Moneal
Rathi, Vikas K.
Yamrozik, June A.
Williams, Ronald B.
Vido, Diane A.
Rayarao, Geetha
Benza, Raymond
Murali, Srinivas
Glass, Jerry
Olson, Peter
Sokos, George
Biederman, Robert W.W.
author_facet Venero, Jose V.
Doyle, Mark
Shah, Moneal
Rathi, Vikas K.
Yamrozik, June A.
Williams, Ronald B.
Vido, Diane A.
Rayarao, Geetha
Benza, Raymond
Murali, Srinivas
Glass, Jerry
Olson, Peter
Sokos, George
Biederman, Robert W.W.
author_sort Venero, Jose V.
collection PubMed
description BACKGROUND: Patients with newly diagnosed dilated cardiomyopathy (DCM) and advanced heart failure have a very high morbidity and mortality with an unpredictable clinical course. We investigated the role of cardiovascular magnetic resonance (CMR) imaging using late gadolinium enhancement (LGE) in this cohort of high‐risk patients. We hypothesized that LGE has high prognostic value in primary DCM patients referred for possible transplantation/left ventricular assist device (LVAD) consideration. METHODS: Over 49 consecutive months, 61 consecutives DCM patients were referred for standard CMR(1.5T, GE) to interrogate the LV pattern, distribution, and extent of LGE (MultiHance, Princeton, NJ). Inclusion criteria for a primary non‐ischaemic DCM and EF <45% were met in 31 patients. DCM patients were categorized into: (i) presence of midwall LV stripe (+Stripe) and (ii) absence of midwall stripe (−Stripe) groups. Primary outcome was defined by the composite of death, need for LV assist device (LVAD), and urgent orthotopic cardiac transplantation (Tx) during a 12‐month follow‐up period. Kaplan–Meier survival analysis was conducted grouping patients by +Stripe and −Stripe. RESULTS: There were no differences between groups for demographics, blood pressure, labs, baseline LVEF, NYHA class, or invasive haemodynamics. There were 18 patients (58%) with +Stripe. Nine events occurred: seven patients required urgent Tx and/or LVAD implantation and two patients died. The +Stripe categorization strongly predicted the need for LVAD, urgent Tx surgery, and death (log‐rank = 9, P = 0.002). All the events occurred in the +Stripe patients with no MACE experienced in the −Stripe group. The −Stripe group experienced marked signs of improvement in LVEF (P = 0.01) at follow‐up. LVEDD was predictive of need for LVAD/Tx and death by univariate analysis. Otherwise, no common clinical metric such as LVEF, LVEDV, RVEF, RVEDV, or any invasive haemodynamic parameter predicted MACE. CONCLUSIONS: The presence of +Stripe on CMR is strongly predictive of LVAD, transplant need, and death during a 12‐month follow‐up period in DCM patients in this proof of concept study. All −Stripe patients survived without experiencing any events. Incorporating CMR imaging into routine clinical practice may have prognostic value in DCM patients; indicating conservative management in low‐risk patients while expectantly managing high‐risk patients.
format Online
Article
Text
id pubmed-5034795
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50347952016-10-03 Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy—preliminary observations from a high‐volume transplant centre Venero, Jose V. Doyle, Mark Shah, Moneal Rathi, Vikas K. Yamrozik, June A. Williams, Ronald B. Vido, Diane A. Rayarao, Geetha Benza, Raymond Murali, Srinivas Glass, Jerry Olson, Peter Sokos, George Biederman, Robert W.W. ESC Heart Fail Original Research Articles BACKGROUND: Patients with newly diagnosed dilated cardiomyopathy (DCM) and advanced heart failure have a very high morbidity and mortality with an unpredictable clinical course. We investigated the role of cardiovascular magnetic resonance (CMR) imaging using late gadolinium enhancement (LGE) in this cohort of high‐risk patients. We hypothesized that LGE has high prognostic value in primary DCM patients referred for possible transplantation/left ventricular assist device (LVAD) consideration. METHODS: Over 49 consecutive months, 61 consecutives DCM patients were referred for standard CMR(1.5T, GE) to interrogate the LV pattern, distribution, and extent of LGE (MultiHance, Princeton, NJ). Inclusion criteria for a primary non‐ischaemic DCM and EF <45% were met in 31 patients. DCM patients were categorized into: (i) presence of midwall LV stripe (+Stripe) and (ii) absence of midwall stripe (−Stripe) groups. Primary outcome was defined by the composite of death, need for LV assist device (LVAD), and urgent orthotopic cardiac transplantation (Tx) during a 12‐month follow‐up period. Kaplan–Meier survival analysis was conducted grouping patients by +Stripe and −Stripe. RESULTS: There were no differences between groups for demographics, blood pressure, labs, baseline LVEF, NYHA class, or invasive haemodynamics. There were 18 patients (58%) with +Stripe. Nine events occurred: seven patients required urgent Tx and/or LVAD implantation and two patients died. The +Stripe categorization strongly predicted the need for LVAD, urgent Tx surgery, and death (log‐rank = 9, P = 0.002). All the events occurred in the +Stripe patients with no MACE experienced in the −Stripe group. The −Stripe group experienced marked signs of improvement in LVEF (P = 0.01) at follow‐up. LVEDD was predictive of need for LVAD/Tx and death by univariate analysis. Otherwise, no common clinical metric such as LVEF, LVEDV, RVEF, RVEDV, or any invasive haemodynamic parameter predicted MACE. CONCLUSIONS: The presence of +Stripe on CMR is strongly predictive of LVAD, transplant need, and death during a 12‐month follow‐up period in DCM patients in this proof of concept study. All −Stripe patients survived without experiencing any events. Incorporating CMR imaging into routine clinical practice may have prognostic value in DCM patients; indicating conservative management in low‐risk patients while expectantly managing high‐risk patients. John Wiley and Sons Inc. 2015-07-29 /pmc/articles/PMC5034795/ /pubmed/27708858 http://dx.doi.org/10.1002/ehf2.12041 Text en © 2015 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research Articles
Venero, Jose V.
Doyle, Mark
Shah, Moneal
Rathi, Vikas K.
Yamrozik, June A.
Williams, Ronald B.
Vido, Diane A.
Rayarao, Geetha
Benza, Raymond
Murali, Srinivas
Glass, Jerry
Olson, Peter
Sokos, George
Biederman, Robert W.W.
Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy—preliminary observations from a high‐volume transplant centre
title Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy—preliminary observations from a high‐volume transplant centre
title_full Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy—preliminary observations from a high‐volume transplant centre
title_fullStr Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy—preliminary observations from a high‐volume transplant centre
title_full_unstemmed Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy—preliminary observations from a high‐volume transplant centre
title_short Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy—preliminary observations from a high‐volume transplant centre
title_sort mid wall fibrosis on cmr with late gadolinium enhancement may predict prognosis for lvad and transplantation risk in patients with newly diagnosed dilated cardiomyopathy—preliminary observations from a high‐volume transplant centre
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034795/
https://www.ncbi.nlm.nih.gov/pubmed/27708858
http://dx.doi.org/10.1002/ehf2.12041
work_keys_str_mv AT venerojosev midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT doylemark midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT shahmoneal midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT rathivikask midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT yamrozikjunea midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT williamsronaldb midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT vidodianea midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT rayaraogeetha midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT benzaraymond midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT muralisrinivas midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT glassjerry midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT olsonpeter midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT sokosgeorge midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre
AT biedermanrobertww midwallfibrosisoncmrwithlategadoliniumenhancementmaypredictprognosisforlvadandtransplantationriskinpatientswithnewlydiagnoseddilatedcardiomyopathypreliminaryobservationsfromahighvolumetransplantcentre